

PATENT

10/044426
11/13/01

#3

1. U.S. Patent 5,516,650;
2. U.S. Patent 5,460,950;


3. EP 0 319 944 A2;
4. EP 0 548 012 B1;
5. Hagen et al., Proc. Natl. Acad. Sci. USA, Vol. 83, pgs. 2412-2416 (1986); and
6. Mather in Goeddel et al., Gene Expression Technology, Methods in Enzymology, Vol. 185, pg. 576 (1990).

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed on filing date of application. Therefore, no fee is due.

Respectfully submitted,

Date: November 13, 2001


Richard W. Bork, Reg. No. 36,459
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE